Positive Results from Phase 3 PROMIS-I Study

Positive Results from Phase 3 PROMIS-I Study of CMS I-Neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting

Zambon, a pharmaceutical company on a mission to innovate cure & care to make patients’ lives better, is pleased to announce the final results from the Phase 3 PROMIS-I study, which were presented at the European Respiratory Society Congress today.

The study, which examined the use of CMS powder for nebulizer solution, delivered by the I-Neb ® AAD system (hereafter referred to as “CMS I-Neb ® ”) for the prevention of pulmonary exacerbations in patients with NCFB, showed CMS I-Neb ® significantly reduced the annual rate of exacerbations and severe exacerbations in patients with NCFB and Pseudomonas aeruginosa chronic infection and prolonged the time to first exacerbation compared to placebo, also improving Quality of Life (QoL). The treatment was demonstrated to be well tolerated…